Clinical Trial Update: Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing neoadjuvant ipilimumab plus nivolumab to standard adjuvant nivolumab in macroscopic Stage III melanoma is active-not-recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Malignant Melanoma Stage III | Phase 3 | Status: ACTIVE_NOT_RECRUITING